Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Castle

Showing results (221-230 of 263) with videos related to

Pageof 27
Sort By:
Psychiatry Research|December 3, 2015
Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophreniaOlivia M Dean, Serafino G Mancuso, Ashley I Bush, et al.
The Medical Journal of Australia|September 19, 2017
The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disordersDavid J Castle, Cherrie A Galletly, Frances Dark, et al.
Psychology & Health|April 25, 2022
Initial evaluation of the Optimal Health Program for people with diabetes: 12-month outcomes of a randomised controlled trialCasey L O'Brien, Pragalathan Apputhurai, Simon R Knowles, et al.
Trials|July 13, 2018
Improving cardiovascular health and quality of life in people with severe mental illness: study protocol for a randomised controlled trialMalcolm Battersby, Michael R Kidd, Julio Licinio, et al.
The Australian and New Zealand Journal of Psychiatry|February 27, 2021
Empirical evidence for cognitive subgroups in body dysmorphic disorderAmy Malcolm, Sarah N Brennan, Sally A Grace, et al.
Addiction (Abingdon, England)|February 5, 2017
Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trialCelene Y L Yap, David McD Taylor, Jonathan C Knott, et al.
CNS Drugs|October 3, 2020
Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover StudyKim S J Lao, Jiaxi Zhao, Joseph Edgar Blais, et al.
Plos One|December 25, 2013
Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and genderDebra L Foley, Andrew Mackinnon, Gerald F Watts, et al.
Annals of Emergency Medicine|October 18, 2016
Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical TrialDavid McD Taylor, Celene Y L Yap, Jonathan C Knott, et al.
Annals of Emergency Medicine|March 25, 2017
In replyDavid M Taylor, Celene Y L Yap, David C M Kong, et al.
Pageof 27

Showing results (221-230 of 263) with videos related to

Sort By:
Pageof 27
Psychiatry Research|December 3, 2015
Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophreniaOlivia M Dean, Serafino G Mancuso, Ashley I Bush, et al.
The Medical Journal of Australia|September 19, 2017
The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disordersDavid J Castle, Cherrie A Galletly, Frances Dark, et al.
Psychology & Health|April 25, 2022
Initial evaluation of the Optimal Health Program for people with diabetes: 12-month outcomes of a randomised controlled trialCasey L O'Brien, Pragalathan Apputhurai, Simon R Knowles, et al.
Trials|July 13, 2018
Improving cardiovascular health and quality of life in people with severe mental illness: study protocol for a randomised controlled trialMalcolm Battersby, Michael R Kidd, Julio Licinio, et al.
The Australian and New Zealand Journal of Psychiatry|February 27, 2021
Empirical evidence for cognitive subgroups in body dysmorphic disorderAmy Malcolm, Sarah N Brennan, Sally A Grace, et al.
Addiction (Abingdon, England)|February 5, 2017
Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trialCelene Y L Yap, David McD Taylor, Jonathan C Knott, et al.
CNS Drugs|October 3, 2020
Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover StudyKim S J Lao, Jiaxi Zhao, Joseph Edgar Blais, et al.
Plos One|December 25, 2013
Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and genderDebra L Foley, Andrew Mackinnon, Gerald F Watts, et al.
Annals of Emergency Medicine|October 18, 2016
Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical TrialDavid McD Taylor, Celene Y L Yap, Jonathan C Knott, et al.
Annals of Emergency Medicine|March 25, 2017
In replyDavid M Taylor, Celene Y L Yap, David C M Kong, et al.
Pageof 27